Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Aura Biosciences, Inc. (AURA)
Company Research
Source: Business Wire
Enrolling Patients in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions; Granted SPA Agreement by FDAData Expected Mid-2024 from Ongoing Phase 1 Trial in Bladder Cancer(Non-Muscle Invasive Bladder Cancer and Muscle Invasive Bladder Cancer)Strong Cash Position into Second Half of 2026 BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights.“We’re excited to expand bel-sar into bladder cancer, as we leverage our therapy’s unique mechanism of action in additional solid cancer indications with major unmet medical need,” said Elisabet de los Pinos, Ph.D., CEO of Aura Biosciences. “Bel-sar is a potential vision-and-organ sparing therapy that we believe will change
Show less
Read more
Impact Snapshot
Event Time:
AURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AURA alerts
High impacting Aura Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
AURA
News
- We're Not Very Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
- Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights [Yahoo! Finance]Yahoo! Finance
- Aura Biosciences to Participate in Upcoming Investor ConferencesBusiness Wire
AURA
Earnings
- 11/9/23 - Beat
AURA
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- AURA's page on the SEC website